Thank you, Mr. Chair.
My petition relates to cystic fibrosis. If we were in the House now, as May is Cystic Fibrosis Awareness Month, one of the days this month we would all be wearing yellow roses in sympathy and solidarity with those who suffer from what is the number one disease killer in Canada of young people.
The petitioners have asked us to look at the situation with the Patented Medicine Prices Review Board, which is scheduled to go through some important and potentially detrimental regulatory changes very soon.
They ask that the amendments to the Patented Medicine Prices Review Board be rescinded, as these will restrict Canadians from receiving life-saving medications for cystic fibrosis and other illnesses, but in particular, a medicine called Trikafta, which can have the effect of treating cystic fibrosis in the case of 90% of cystic fibrosis sufferers. They ask the government to work with the provinces to find a strategy to jointly allow for the delivery of this life-saving medicine to Canadians across the country and to take a leadership role in negotiating a price for gene modulators throughout all the provinces of Canada.